Key Points
- CEO Christopher Peetz sold 40,985 shares on March 16 at an average price of $91.98 for $3.77M, reducing his stake by 17.42% to 194,309 shares (about $17.87M).
- Multiple other executives also sold meaningful blocks the same day, a clustered insider sale worth several million dollars that may be perceived as profit‑taking and could pressure the stock despite insiders retaining significant equity.
- Company outlook: Mirum completed enrollment in the Phase 3 EXPAND study of Livmarli (topline data expected Q4 2026); the firm reported ~50% revenue growth year‑over‑year but missed EPS estimates, and analysts maintain a consensus "Moderate Buy" with an average target of $117.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 4,732 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $435,249.36. Following the transaction, the senior vice president owned 8,429 shares in the company, valued at approximately $775,299.42. This represents a 35.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Jolanda Howe also recently made the following trade(s):
- On Monday, February 2nd, Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $103.30, for a total value of $99,994.40.
- On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total value of $80,991.98.
- On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $86,423.58.
Mirum Pharmaceuticals Stock Performance
Mirum Pharmaceuticals stock opened at $96.55 on Wednesday. The stock's 50 day moving average price is $96.13 and its 200 day moving average price is $81.00. The firm has a market capitalization of $5.83 billion, a PE ratio of -201.14 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $109.28.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same period last year, the business earned $1.00 EPS. The firm's revenue was up 49.8% compared to the same quarter last year. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.
More Mirum Pharmaceuticals News
Here are the key news stories impacting Mirum Pharmaceuticals this week:
- Positive Sentiment: Mirum completed enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases, a key clinical milestone that keeps the program on track; topline data are expected in Q4 2026. This is a material near‑term catalyst that can materially re‑rate the stock if results are positive. Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli Mirum Completes Enrollment (Yahoo)
- Negative Sentiment: Multiple insiders (CEO Christopher Peetz, COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe and Joanne Quan) sold meaningful blocks of shares on March 16 — collectively several million dollars at an average price of ~$91.98 — reducing their holdings by double‑digit percentages. Large, clustered insider sales can be perceived as profit‑taking or concern about near‑term upside and may put pressure on the stock even though insiders still retain significant equity. SEC filings: Peetz Form 4 Radovich Form 4 Bjerkholt Form 4 Howe Form 4 Quan Form 4
Institutional Trading of Mirum Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in MIRM. Janus Henderson Group PLC boosted its stake in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. State Street Corp increased its position in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company's stock worth $169,354,000 after purchasing an additional 797,088 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock worth $57,965,000 after purchasing an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company's stock valued at $44,889,000 after purchasing an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC raised its stake in shares of Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company's stock valued at $28,560,000 after purchasing an additional 371,999 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on MIRM shares. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an "outperform" rating in a report on Monday, December 8th. Stifel Nicolaus upped their price objective on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Royal Bank Of Canada cut their price target on Mirum Pharmaceuticals from $130.00 to $128.00 and set an "outperform" rating on the stock in a research note on Thursday, February 26th. Finally, Morgan Stanley increased their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an "overweight" rating in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $117.00.
Read Our Latest Stock Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
